Effect of curcuminoids supplementation in treatment of methadone maintenance treatment patients

Clinical trial of the effect of curcuminoids supplementation compared with the placebo on mental health parameters and metabolic profiles in methadone maintenance treatment patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170420033551N8

Enrollment

Registered

2019-08-18

Start date

2019-07-05

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction. Other psychoactive substance related disorders

Interventions

Intervention 1: Intervention group: capsule contains 80 mg curcuminoids (Zahravi, Tabriz, Iran), daily, for 12 weeks orally. Intervention 2: Control group: curcuminoids placebos capsule (Barij essence

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients under methadone maintenance treatment Individuals aged 18 to 70 years

Exclusion criteria

Exclusion criteria: Unwillingness to cooperate Suicide attempts within the past 12 months or either suicidal ideations or psychotic symptoms in the past 6 months as determined by a study physician Current opioid, alcohol or sedative physical dependence or cocaine dependence Major cardiovascular disorder Present or recent use (within 2 weeks) of over-the-counter or prescription drug that would be expected to have major interaction with curcuminoid Metabolic diseases

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Depression Inventory (BDI).;Anxiety. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Anxiety Inventory (BAI).;Sleep quality. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).	—

Measure

Time frame

Depression. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Depression Inventory (BDI).;Anxiety. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Anxiety Inventory (BAI).;Sleep quality. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).

—

Secondary

Measure	Time frame
Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Ghaderi

Kashan University of Medical Sciences

gaderiam@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026